PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer

Review of 2 RCTs (n=361) found that, in a recurrent disease setting, mTOR inhibitors may result in improved progression‐free survival, but there was no clear benefit in overall survival or tumour response rate. Publication of at least 5 ongoing studies is awaited.


Cochrane Database of Systematic Reviews